ABS heads into the new millennium having established the groundwork to
make the transition to new commercial prosperity. As new clinical data
validate the company's diagnostic program and bring it to the point of
bearing fruit, ABS stockholders would be justified in looking
confidently to a future with significant investor returns.
The preceding year has also seen considerable success in ABS'
neuroscience program, which is the second prong in the company's ongoing
strategy. ABS-103 is showing great promise as a candidate for replacing
valproic acid (valproate), one of the most widely prescribed medicines
in the world for the treatment of epilepsy and the mania associated with
bipolar (manic) depression as well as preventing the onset of migraine
headaches. Each year, valproate generates more than $1 billion in
revenue. ABS-103 was engineered to have the same efficacy as valproate,
but without the dangerous side effects of that widely prescribed drug.
The single isomer refined version of ABS-103 has shown itself in
clinical trials to be less toxic yet, and has become the company's
preferred candidate for imminent licensing to a large pharmaceutical
Premier médicament viagra generique en France en ligne.
ABS-205, another promising candidate in the neuroscience program, is offering
the world new hope for the treatment of Alzheimer's
disease. Shown in research to produce effects similar
to the nerve growth factor NGF, ABS-205 can help maintain
pathways to the brain, and cross the blood-brain barrier
-- both essential features in treating Alzheimer's
and other neurological conditions.